166 related articles for article (PubMed ID: 11249670)
1. Molecular genetic analysis of herpesviruses and their potential use as vectors for gene therapy applications.
Cotter MA; Robertson ES
Curr Opin Mol Ther; 1999 Oct; 1(5):633-44. PubMed ID: 11249670
[TBL] [Abstract][Full Text] [Related]
2. Epstein-Barr virus vectors for gene delivery to B lymphocytes.
Robertson ES; Ooka T; Kieff ED
Proc Natl Acad Sci U S A; 1996 Oct; 93(21):11334-40. PubMed ID: 8876136
[TBL] [Abstract][Full Text] [Related]
3. Development of a novel helper-dependent adenovirus-Epstein-Barr virus hybrid system for the stable transformation of mammalian cells.
Dorigo O; Gil JS; Gallaher SD; Tan BT; Castro MG; Lowenstein PR; Calos MP; Berk AJ
J Virol; 2004 Jun; 78(12):6556-66. PubMed ID: 15163748
[TBL] [Abstract][Full Text] [Related]
4. Chromatin-binding regions of EBNA1 protein facilitate the enhanced transfection of Epstein-Barr virus-based vectors.
Howden SE; Wardan H; Voullaire L; McLenachan S; Williamson R; Ioannou P; Vadolas J
Hum Gene Ther; 2006 Aug; 17(8):833-44. PubMed ID: 16942443
[TBL] [Abstract][Full Text] [Related]
5. Herpes simplex virus type 1 amplicons and their hybrid virus partners, EBV, AAV, and retrovirus.
Oehmig A; Fraefel C; Breakefield XO; Ackermann M
Curr Gene Ther; 2004 Dec; 4(4):385-408. PubMed ID: 15578989
[TBL] [Abstract][Full Text] [Related]
6. Contribution of viral recombinants to the study of the immune response against the Epstein-Barr virus.
Delecluse HJ; Feederle R; Behrends U; Mautner J
Semin Cancer Biol; 2008 Dec; 18(6):409-15. PubMed ID: 18938248
[TBL] [Abstract][Full Text] [Related]
7. Establishment and applications of epstein-barr virus-based episomal vectors in human embryonic stem cells.
Ren C; Zhao M; Yang X; Li D; Jiang X; Wang L; Shan W; Yang H; Zhou L; Zhou W; Zhang H
Stem Cells; 2006 May; 24(5):1338-47. PubMed ID: 16410388
[TBL] [Abstract][Full Text] [Related]
8. Efficient gene delivery into epstein-barr virus (EBV)-transformed human B cells mediated by replication-defective herpes simplex virus-1 (HSV-1): A gene therapy model for EBV-related B cell malignancy.
Suzuki T; Piche A; Kasono K; Xiang J; Gomez-Navarro J; Moriuchi S; Krisky DM; Oligino T; Glorioso JC; Curiel TJ; Curiel DT
Biochem Biophys Res Commun; 1998 Nov; 252(3):686-90. PubMed ID: 9837767
[TBL] [Abstract][Full Text] [Related]
9. Eradication of Epstein-Barr virus episome and associated inhibition of infected tumor cell growth by adenovirus vector-mediated transduction of dominant-negative EBNA1.
Nasimuzzaman M; Kuroda M; Dohno S; Yamamoto T; Iwatsuki K; Matsuzaki S; Mohammad R; Kumita W; Mizuguchi H; Hayakawa T; Nakamura H; Taguchi T; Wakiguchi H; Imai S
Mol Ther; 2005 Apr; 11(4):578-90. PubMed ID: 15771960
[TBL] [Abstract][Full Text] [Related]
10. HCF1 and OCT2 Cooperate with EBNA1 To Enhance OriP-Dependent Transcription and Episome Maintenance of Latent Epstein-Barr Virus.
Dheekollu J; Wiedmer A; Sentana-Lledo D; Cassel J; Messick T; Lieberman PM
J Virol; 2016 Jun; 90(11):5353-5367. PubMed ID: 27009953
[TBL] [Abstract][Full Text] [Related]
11. Maintenance of Epstein-Barr virus-derived episomal vectors in the murine Sp2/0 myeloma cell line is dependent upon exogenous expression of human EBP2.
Habel ME; Drouin M; Jung D
Biochem Cell Biol; 2004 Jun; 82(3):375-80. PubMed ID: 15181471
[TBL] [Abstract][Full Text] [Related]
12. Use of Epstein-Barr virus nuclear antigen-1 in targeted therapy of EBV-associated neoplasia.
Judde JG; Spangler G; Magrath I; Bhatia K
Hum Gene Ther; 1996 Mar; 7(5):647-53. PubMed ID: 8845390
[TBL] [Abstract][Full Text] [Related]
13. Infectious delivery of 120-kilobase genomic DNA by an epstein-barr virus amplicon vector.
White RE; Wade-Martins R; James MR
Mol Ther; 2002 Apr; 5(4):427-35. PubMed ID: 11945070
[TBL] [Abstract][Full Text] [Related]
14. An episomally maintained MDR1 gene for gene therapy.
Lee CG; Vieira WD; Pastan I; Gottesman MM
Hum Gene Ther; 2001 May; 12(8):945-53. PubMed ID: 11387059
[TBL] [Abstract][Full Text] [Related]
15. CRISPR/Cas9-Mediated Genome Editing of Herpesviruses Limits Productive and Latent Infections.
van Diemen FR; Kruse EM; Hooykaas MJ; Bruggeling CE; Schürch AC; van Ham PM; Imhof SM; Nijhuis M; Wiertz EJ; Lebbink RJ
PLoS Pathog; 2016 Jun; 12(6):e1005701. PubMed ID: 27362483
[TBL] [Abstract][Full Text] [Related]
16. BZLF1 controlled by family repeat domain induces lytic cytotoxicity in Epstein-Barr virus-positive tumor cells.
Wang H; Zhao Y; Zeng L; Tang M; El-Deeb A; Li JJ; Cao Y
Anticancer Res; 2004; 24(1):67-74. PubMed ID: 15015577
[TBL] [Abstract][Full Text] [Related]
17. The functional role of S/MARs in episomal vectors as defined by the stress-induced destabilization profile of the vector sequences.
Giannakopoulos A; Stavrou EF; Zarkadis I; Zoumbos N; Thrasher AJ; Athanassiadou A
J Mol Biol; 2009 Apr; 387(5):1239-49. PubMed ID: 19248788
[TBL] [Abstract][Full Text] [Related]
18. A hybrid herpesvirus infectious vector based on Epstein-Barr virus and herpes simplex virus type 1 for gene transfer into human cells in vitro and in vivo.
Wang S; Vos JM
J Virol; 1996 Dec; 70(12):8422-30. PubMed ID: 8970963
[TBL] [Abstract][Full Text] [Related]
19. DNA ligand designed to antagonize EBNA1 represses Epstein-Barr virus-induced immortalization.
Yasuda A; Noguchi K; Minoshima M; Kashiwazaki G; Kanda T; Katayama K; Mitsuhashi J; Bando T; Sugiyama H; Sugimoto Y
Cancer Sci; 2011 Dec; 102(12):2221-30. PubMed ID: 21910783
[TBL] [Abstract][Full Text] [Related]
20. EBV replicon vector system enhances transgene expression in vivo: applications to cancer gene therapy.
Otomo T; Yamamoto S; Morishita R; Kaneda Y
J Gene Med; 2001; 3(4):345-52. PubMed ID: 11529664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
